Pulmonary arterial hypertension in systemic lupus erythematosus: Should we bother?

Rheumatology

Volumn 48, Issue 12, 2009, Pages 1471-1472

  Bijl, Marc ^a   Bootsma, Hendrika ^a   Kallenberg, Cees G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ENDOGLIN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; INTERLEUKIN 8; PHOSPHODIESTERASE V INHIBITOR; PLATELET DERIVED GROWTH FACTOR; PROSTANOID; TRANSFORMING GROWTH FACTOR BETA2; TUMOR NECROSIS FACTOR ALPHA;

COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; EDITORIAL; HIGH RISK PATIENT; HUMAN; LUNG ARTERY PRESSURE; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RELIABILITY; RISK FACTOR; SCREENING TEST; SURVIVAL RATE; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS;

EARLY DIAGNOSIS; HUMANS; HYPERTENSION, PULMONARY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MASS SCREENING;

EID: 75649126824     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep258     Document Type: Editorial

References (11)

1. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996;35:989-93.
2. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
3. Badesch DB, Hill NS, Burgess G et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 2007;34:2417-22.
4. Condliffe R, Kiely DG, Peacock AJ et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009;179:151-7.
5. McGoon M, Gutterman D, Steen V et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:14S-34S.
6. Prabu A, Kiran P, Yee C-S et al. Prevalence and risk factors for pulmonary artery hypertension in lupus. Rheumatology 2009;48:1506-11.
7. Mukerjee D, St George D, Knight C et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology 2004;43:461-6.
8. McQuillan BM, Picard MH, Leavitt M, Weyman AE. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation 2001;104:2797-802.
9. Williams MH, Handler CE, Akram R et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 2006;27:1485-94.
10. Coral-Alvarado P, Quintana G, Garces MF et al. Potential biomarkers for detecting pulmonary arterial hypertension in patients with systemic sclerosis. Rheumatol Int 2009;29:1017-24.
11. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003;48: 516-22.